Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Increasing Skin Permeability to Improve Drug Delivery

XTALKS VITALS NEWS

Skin

Researchers from Shizuoka University in Japan have developed a method using atmospheric microplasma to disrupt this impermeable layer of the skin.

Share this!

November 22, 2016 | by Sarah Hand, M.Sc.

Transdermal drug delivery represents a promising way to administer active ingredients through the skin. Unfortunately, drug developers face considerable challenges when designing therapeutics that are able to pass through the tough outer layer of the skin, known as the stratum corneum.

While the stratum corneum protects the lower levels of skin cells from infection, it also prevents most drugs applied topically from passively diffusing into the blood stream. Now, researchers from Shizuoka University in Japan have developed a method using atmospheric microplasma to disrupt this impermeable layer.

Using conductive and non-conductive materials, the researchers tested the effects of the plasma treatment on the stratum corneum of pig skin. The results of their study were presented at the 63rd Annual Symposium and Exhibition of the American Vacuum Society (AVS).



When the researchers used a conductive material, the plasma jet caused significant damage to the skin samples. Conversely, the non-conductive material using atmospheric microplasma caused no damage to the skin.

This non-conductive microplasma treatment also increased the permeability of the skin, as demonstrated using a dye test. While skin is normally impermeable to dyes, the microplasma treatment allowed the dye to enter the skin through the stratum corneum, suggesting that the same results could be seen with drug products.

While the technique seems promising, the researchers will need to conduct further preclinical tests before microplasma can be used to improve transdermal drug delivery in humans. As skin is the largest organ in the human body, care will need to be taken to ensure that this technique does not permanently disrupt this important barrier.


Keywords: Skin, Drug Delivery, Preclinical


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
New Self-Injectable Form of Lupus Drug Approved by the FDA

July 25, 2017 - Patients with systemic lupus erythematosus (SLE) will now have the option to self-inject their medication thanks to the FDA approval of GSK’s reformulated lupus drug, Benlysta (belimumab).

Featured In: Biotech News


Canadian Chicken Farmers to Further Reduce Use of Antibiotics

July 24, 2017 - The Chicken Farmers of Canada, a national group dedicated to supporting poultry farmers and helping them meet consumer demand for chicken, has announced their strategy for eliminating the use of certain antimicrobials in meat production.

Featured In: Food News


Neonatal MRI Medical Device Approved by the FDA

July 24, 2017 - Medical device maker Aspect Imaging has received US Food and Drug Administration (FDA) approval for its Embrace Neonatal MRI System.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.